Andreas Wicki
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch C, Roth B, Bosshard P, Püschel H, Boll D, Hefermehl L, Roghmann F, Gierth M, Ribi K, Schäfer S, Wicki A, Bubendorf L, Torpai R, Thalmann G, Lucca I, Kwiatkowski M, Wirth G, Strebel R, Engeler D, Pedrazzini A, Hüttenbrink C, Schultze-Seemann W, Hayoz S. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. Eur Urol Oncol 2022; 5:195-202.
07.01.2022A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
07.01.2022Eur Urol Oncol 2022; 5:195-202
Rentsch Cyrill A, Roth Beat, Bosshard Piet, Püschel Heike, Boll Daniel T, Hefermehl Lukas, Roghmann Florian, Gierth Michael, Ribi Karin, Schäfer Simon, Wicki Andreas, Bubendorf Lukas, Torpai Raimund, Thalmann George N, Lucca Ilaria, Kwiatkowski Maciej, Wirth Grégory J, Strebel Räto T, Engeler Daniel, Pedrazzini Augusto, Hüttenbrink Clemens, Schultze-Seemann Wolfgang, Hayoz Stefanie
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
Kienle D, Andrieu C, Bernhard J, Lugli A, Baertschi D, Helbling D, Saletti P, Kueng M, Bastian S, Horber D, Koeberle D, Winterhalder R, Quagliata L, Wicki A, Ribi K, Dietrich D, von Moos R. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. J Geriatr Oncol 2018; 10:304-310.
14.12.2018Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
14.12.2018J Geriatr Oncol 2018; 10:304-310
Kienle Dirk L, Andrieu Christiane, Bernhard Juerg, Lugli Alessandro, Baertschi Daniela, Helbling Daniel, Saletti Piercarlo, Kueng Marc, Bastian Sara, Horber Daniel, Koeberle Dieter, Winterhalder Ralph C, Quagliata Luca, Wicki Andreas, Ribi Karin, Dietrich Daniel, von Moos Roger
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Wicki A, Tzankov A, Hess V, Childs A, Hierro C, Rodón J, Hess D, Jörger M, von Moos R, Sessa C, Ritschard R, Prêtre V, Herrmann R, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer 2018; 96:6-16.
13.04.2018First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
13.04.2018Eur J Cancer 2018; 96:6-16
Wicki Andreas, Tzankov Alexandar, Hess Viviane, Childs Alexa, Hierro Cinta, Rodón Jordi, Hess Dagmar, Jörger Markus, von Moos Roger, Sessa Cristiana, Ritschard Reto, Prêtre Vincent, Herrmann Richard, Brown Nicholas, Xyrafas Alexandros, Bize Vincent, Hawle Hanne, Berardi Simona, Cmiljanović Nataša, Cmiljanović Vladimir, Stumm Michael, Dimitrijević Saša, Kristeleit Rebecca
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC cancer 2016; 16:780.
10.10.2016SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
10.10.2016BMC cancer 2016; 16:780
Rochlitz Christoph, Rordorf Tamara, Rauch Daniel, Müller Andreas, Ruhstaller Thomas, Vetter Marcus, Trojan Andreas, Hasler-Strub Ursula, Cathomas Richard, Winterhalder Ralph, Borner Markus, Bärtschi Daniela, Bigler Martin, von Moos Roger, Bernhard Jürg, Matter-Walstra Klazien, Wicki Andreas, Zaman Khalil, Anchisi Sandro, Küng Marc, Na Kyung-Jae